Valuation: Lineage Cell Therapeutics, Inc.

Market Cap 260M 227M 214M 195M 365M 25B 366M 2.57B 991M 12.71B 979M 957M 40.89B P/E 2026 *
-15.3x
P/E 2027 * -9.88x
Enterprise Value 260M 227M 214M 195M 365M 25B 366M 2.57B 991M 12.71B 979M 957M 40.89B EV / Sales 2026 *
17.1x
EV / Sales 2027 * 15.5x
Free-Float
95.14%
Yield 2026 *
-
Yield 2027 * -
1 week+1.98%
Current month-6.36%
1 month-2.83%
3 months-14.88%
6 months-31.33%
Current year-38.32%
1 week 1
Extreme 1
1.12
1 month 1
Extreme 1
1.18
Current year 1
Extreme 1
1.98
1 year 1
Extreme 1
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.71
10 years 0.37
Extreme 0.3651
4
Manager TitleAgeSince
Chief Executive Officer 54 2018-09-16
Director of Finance/CFO 50 2022-11-13
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 60 2009-06-30
Director/Board Member 68 2014-04-10
Chairman 60 2024-04-26
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/26 Free

Director

125,000 0.0501%
7/1/26
Broadwood Capital, Inc.
FreeCompany 125,000 0.0501%
7/1/26 Free

Director

125,000 0.0501%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.98%-33.55%-21.37% 260M
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+40.07%+27.26% 43.85B
-3.04%-6.29%+322.27%+517.36% 40.93B
-0.74%+1.25%+2.32%+67.94% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+21.99%+124.21% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.15%+38.93% 15.22B
-3.14%+31.91%-10.60% - 14.05B
Average -0.89%+3.58%+41.86%+102.93% 26.26B
Weighted average by Cap. -1.02%+1.87%+64.59%+130.06%

Financials

2026 *2027 *
Net sales 15.19M 13.25M 12.51M 11.36M 21.28M 1.46B 21.37M 150M 57.83M 741M 57.07M 55.81M 2.38B 16.83M 14.68M 13.86M 12.59M 23.58M 1.62B 23.68M 166M 64.07M 821M 63.24M 61.83M 2.64B
Net income -22.64M -19.74M -18.64M -16.93M -31.72M -2.17B -31.85M -223M -86.17M -1.1B -85.05M -83.16M -3.55B -34.44M -30.03M -28.36M -25.75M -48.24M -3.3B -48.45M -340M -131M -1.68B -129M -127M -5.41B
Net Debt - -
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
26-09-18 $1.030 0.00% 3,209,250
26-09-17 $1.030 -3.74% 901,699
26-09-16 $1.070 +0.94% 1,639,485
26-09-15 $1.060 -0.93% 1,400,035
26-09-14 $1.070 +5.94% 1,840,125
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.030USD
Average target price
5.500USD
Spread / Average Target
+433.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LCTX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!